Node metastasis were substantial predictors of PFS. Nevertheless each anti-p53 antibody and IHC of p53 protein negativity didn’t yield any independent predictive aspects (Table three).Discussion To our expertise, this retrospective study will be the very first to evaluate the predictive significance of the presence ofTable three Univariate and multivariate analysisUnivariate analysis OS Gender (male or female) Age (65 or 2^ 65) Overall performance status (0 or 1) Resection of primary tumor (yes or no) Ascitis (yes or no) Liver metastasis (yes or no) Lung metastasis (yes or no) Lymph metastasis (yes or no) Numerous metastasis (yes or no) Peritoneal metastasis (yes or no) Anti p53 antibody (optimistic or negative) IHC of p53 protein (constructive or negative) KRAS (wild or mutant) PFS Gender (male or female) Age (65 or^65) Functionality status (0 or 1) Resection of principal tumor (yes or no) Ascitis (yes or no) Liver metastasis (yes or no) Lung metastasis (yes or no) Lymph metastasis (yes or no) Various metastasis (yes or no) Peritoneal metastasis (yes or no) Anti p53 antibody (good or unfavorable) IHC of p53 protein (positive or damaging) KRAS (wild or mutant) Multivariate analysis OS Peritoneal metastasis (yes or no) PFS Lung metastasis (yes or no) Lymph metastasis (yes or no) two.Formula of 957770-66-0 46 0.448-61-3 web 5 HR 2.three 1.six 0.99 1.eight 1.5 0.six 0.54 2.eight 0.47 0.9 0.73 0.9 1 0.98 HR 0.76 0.98 1.78 0.7 1.7 1.two 0.77 1.9 2.5 2.5 0.eight 0.58 1.anti-p53 antibodies and its correlation together with the KRAS genotype in CRC sufferers treated with first-line chemotherapy. No correlation was observed in between anti-p53 antibody positivity and ORR. Additionally, no correlation was observed amongst anti-p53 antibody positivity and also the KRAS genotype. The mechanism underlying anti-p53 auto-antibody production has but to become revealed but is believed to be associated with all the presence of your TP53 mutation and p53 protein overexpression. Anti-p53 autoantibody frequency was then correlated with reported TP53 mutation rates toLower 95 CI 0.34 0.94 0.42 0.2 0.7 0.59 0.34 0.86 1.1 1.two 0.3 0.21 0.Upper 95 CI 1.67 1.03 7.five 1.6 four.1 2.six 1.7 four.2 5.9 5.2 1.7 1.six 2.p.worth 0.five 0.5 0.43 0.43 0.22 0.55 0.51 0.1 0.03 0.01 0.61 0.3 0.0.9 0.96 0.23 0.72 0.28 0.28 1.PMID:35901518 59 0.26 0.51 0.37 0.49 0.51 0.three.03 1.02 2.47 3.1 1.43 1 5.two 0.85 1.six 1.45 1.six 1.9 1.0.1 0.53 0.64 0.99 0.29 0.07 4E-04 0.01 0.72 0.27 0.73 0.99 0.94 p.value 0.Lower 95 CI 1.Upper 95 CI 5.1.34 0.4.51 0.0.003 0.Osumi et al. BMC Cancer (2015) 15:Page 7 ofTable 4 p53 status and prognosis of colorectal cancer: previous literature dateReference n Histology therapy Techniques for IHC Sequencing Frequency Prognostic worth determing alterd p53 All round survial Survival p53 Ab pathway ( ) + + + + + + + 37.6(IHC) 41.8DtHCD 65 OHCD 57 OHCD 51.5(IHC) 47(IHC) 32(S) Samowitz WS [16] Chang SC [17] 1464 ACC 167 ACC biopsy and surgery surgery + + + 45.4DSD 28.1(Ab) 56.three(S) Angelopoulou K [18] 229 Kressner U [19] Suppiah A [20] Kreessner U [21] 184 28 294 ACC ACC ACC ACC biopsy and surgery + surgery surgery biopsy + + + 23(Ab) 32(Ab) 21,7(Ab) 55DAbD univariate NA univariate univariate NS univariate murtivariate univariate univariate murtivariate NS univariate NS NS NS NA NS NA NA NA NA NA NA NA NA NA NA Response NALAN YT [10] Triantafyllou K [11] Wang Q [12] Hu J [13] Grewal H [14]258 55 40 120ACCsurgeryAdenoma Polypectomy ACC ACC ACC ACC surgerymurtivariate NA NA NA NA NA NA NA NA NAbiopsy and surgery surgery surgery -Bouzourenne H [15]Ab antibody; IHC immunohistochemistry; S sequencing; ACC sophisticated colorect.